In contrast, this dendritic cell-based immunotherapy aims to induce a new, specific immune response against the tumor." Describing the strategy, study co-supervisor Stefanie Wculek—formerly at ...

The drug is also in mid-stage clinical development for ovarian granulosa cell tumors, a rare type of ovarian cancer that currently has no FDA-approved therapies. Through partnerships, the twice ...

Results from a phase 1 trial showed the independently reviewed best overall objective response rate was 71% in emactuzumab-treated patients. The Food and Drug Administration (FDA) has granted Fast ...

called adaptive NK cells, to remember ovarian tumors and effectively attack them. The discovery, published in Cancer Immunology Research, could pave the way for new, more powerful immunotherapies for ...

(Wanglab) Researchers at the Viterbi School of Engineering published a study at the beginning of April detailing their work using ultrasound on Chimeric antigen receptor T-cells to target solid tumors ...

the EchoBack CAR T-cell, that uses focused ultrasound to activate and sustain a powerful, targeted attack on tumors. Unlike earlier versions, these cells remain effective for days without tiring ...

Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints ...